InspireMD/$NSPR
About InspireMD
Ticker
Industry
Headquarters
Employees
InspireMD Metrics
$83M
-
-$0.74
0.98
-
Price and volume
Market cap
$83M
Beta
0.98
52-week high
$3.42
52-week low
$1.81
Average daily volume
41K
Financial strength
Current ratio
6.386
Quick ratio
5.874
Long term debt to equity
1.649
Total debt to equity
1.649
Management effectiveness
Return on assets (TTM)
-37.24%
Return on equity (TTM)
-66.75%
Valuation
Price to revenue (TTM)
17.756
Price to book
1.98
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
-5.879
Growth
Revenue change (TTM)
24.70%
Earnings per share change (TTM)
-31.36%
3-year revenue growth (CAGR)
27.73%
3-year earnings per share growth (CAGR)
-32.62%
What the Analysts think about InspireMD
Analyst Ratings
InspireMD Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
InspireMD Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
InspireMD News

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
What’s the current market cap for InspireMD stock?
What is the P/E ratio for InspireMD stock?
Does InspireMD stock pay dividends?
No, InspireMD (NSPR) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next InspireMD dividend payment date?
InspireMD (NSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for InspireMD?
InspireMD (NSPR) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.